Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin-1 + Rituximab in Refractory Indolent B-cell NHL and CLL
NCT00087425Phase 2Completed
- Sponsor
- National Institute on Aging
- Start
- Jul 2004
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bryostatin-1 in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL), sponsored by National Institute on Aging. Primary endpoints: Feasibility and safety of bryostatin 1 and rituximab and Antitumor response. Started Jul 2004; status: completed.
02
Drugs
bryostatin-1
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00087425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087425.